期刊文献+

Human Vγ9Vδ2-T cells efficiently kill influenzavirus-infected lung alveolar epithelial cells 被引量:3

Human Vγ9Vδ2-T cells efficiently kill influenzavirus-infected lung alveolar epithelial cells
原文传递
导出
摘要 γδ-T cells play an indispensable role in host defense against different viruses, including influenza A virus. However, whether these cells have cytotoxic activity against influenza virus-infected lung alveolar epithelial cells and subsequently contribute to virus clearance remains unknown. Using influenza virus-infected A549 cells, human lung alveolar epithelial cells, we investigated the cytotoxic activity of aminobisphosphonate pamidronate (PAM)-expanded human Vγ9Vδ2-T cells and their underlying mechanisms. We found that PAM could selectively activate and expand human Vγ9Vδ2-T cells. PAM-expanded human Vγ9Vδ2-T cells efficiently killed influenza virus-infected lung alveolar epithelial cells and inhibited virus replication. The cytotoxic activity of PAM-expanded Vγ9Vδ2-T cells was dependent on cell-to-cell contact and required NKG2D activation. Perforin-granzyme B, tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas-Fas ligand (FasL) pathways were involved in their cytotoxicity. Our study suggests that targeting γδ2-T cells by PAM can potentially offer an alternative option for the treatment of influenza virus. γδ-T cells play an indispensable role in host defense against different viruses, including influenza A virus. However, whether these cells have cytotoxic activity against influenza virus-infected lung alveolar epithelial cells and subsequently contribute to virus clearance remains unknown. Using influenza virus-infected A549 cells, human lung alveolar epithelial cells, we investigated the cytotoxic activity of aminobisphosphonate pamidronate (PAM)-expanded human Vγ9Vδ2-T cells and their underlying mechanisms. We found that PAM could selectively activate and expand human Vγ9Vδ2-T cells. PAM-expanded human Vγ9Vδ2-T cells efficiently killed influenza virus-infected lung alveolar epithelial cells and inhibited virus replication. The cytotoxic activity of PAM-expanded Vγ9Vδ2-T cells was dependent on cell-to-cell contact and required NKG2D activation. Perforin-granzyme B, tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas-Fas ligand (FasL) pathways were involved in their cytotoxicity. Our study suggests that targeting γδ2-T cells by PAM can potentially offer an alternative option for the treatment of influenza virus.
出处 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2013年第2期159-164,共6页 中国免疫学杂志(英文版)
基金 This work was supported in part by the National Natural Science Foundation of China (No. 30973235), Science and Technology Project of the Sichuan Science and Technology Department (2010SZ0110), General Research Fund, Research Grants Council of Hung Kong (HKU 781211M) and the Area of Excellence Scheme of the University Grants Committee, Hung Kong SAR, China (AoE/M-12/06).
关键词 A549 cells influenza A virus PAM Vγ9Vδ2 T cell A549 cells influenza A virus PAM Vγ9Vδ2 T cell
  • 相关文献

参考文献2

二级参考文献37

  • 1Peng L, Shu S Krauss JC. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immuno11997; 178: 24-32.
  • 2Rosenberg SA, Spiess P, Lafreniere R. A new approach tothe adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-1321.
  • 3Plautz GE, Bukowski RM, Novick AC, Klein EA, Kursh ED, Olencki TE et al T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology1999; 54: 617-623; discussion 623-614.
  • 4Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL etalAdoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24: 363-373.
  • 5Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675.
  • 6Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti- tumor reactivity. J Immuno11999; 163: 507-513.
  • 7Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR etaL High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immuno12003; 171: 3287-3295.
  • 8Hughes MS, Yu YY, Dudley M E, Zheng Z, Robbins PF, Li Y etal Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene TheY2005; 16: 457-472.
  • 9Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball Jet al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immuno12001; 2: 962-970.
  • 10Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM etal. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.

共引文献22

同被引文献5

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部